Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Gomez-Roca

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Nature Communications|March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human studyYonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Cancer Immunology Research|April 17, 2020
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial MalignanciesCamille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib studyJose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen, et al.
Cancer Discovery|April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase EpsilonBenoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Nature Communications|March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human studyYonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Cancer Immunology Research|April 17, 2020
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial MalignanciesCamille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib studyJose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen, et al.
Cancer Discovery|April 10, 2022
PD-1 Blockade in Solid Tumors with Defects in Polymerase EpsilonBenoit Rousseau, Ivan Bieche, Eric Pasmant, et al.
Pageof 8